https://scholars.lib.ntu.edu.tw/handle/123456789/189673
標題: | Liraglutide, a Once-Daily Human Glp-1 Analogue, Added to a Sulphonylurea over 26 Weeks Produces Greater Improvements in Glycaemic and Weight Control Compared with Adding Rosiglitazone or Placebo in Subjects with Type 2 Diabetes (Lead-1 Su) | 作者: | CHUANG, LEE-MING | 關鍵字: | dipeptidyl peptidase-4 glucagon-like peptide-1 receptor agonist incretin insulinotropic thiazolidinedione | 公開日期: | 2009 | 卷: | v.26 | 期: | n.3 | 起(迄)頁: | 268-278 | 來源出版物: | DIABETIC MEDICINE | 摘要: | Abstract: To compare the effects of combining liraglutide (0 .6, 1.2 or 1 .8 mg/day) or rosiglitazone 4 mg/day (all n >= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes . In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 + /- 1.0 % at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study. Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA(1c) from baseline, (-1.1% , baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone(-0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride . Liraglutide 0.6 mg was less effective (-0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1. 2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0 .006, baseline 9 .9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [-2.5 to -2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (-0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0. 05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1.8 mg (-0. 2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (- 0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg). Main adverse events for all treatments were minor hypoglycaemia ( < 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%) . baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0 . 05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1 .8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/188622 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。